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The protein encoded by ORF 4 of mouse hepatitis virus (MHV) is not required for growth of some strains in tissue culture
cells, but its role in pathogenesis in the murine host has not been defined previously in a controlled manner. MHV strain JHM
causes acute and chronic neurological diseases in susceptible strains of rodents. To genetically manipulate the structural
proteins of this and other strains of MHV, we have generalized an interspecies-targeted RNA recombination selection that
was originally developed for the A59 strain of MHV. Using this approach, a recombinant MHV–JHM was constructed in which
gene 4 was genetically inactivated. Virus lacking gene 4 expression replicated in tissue culture cells with similar kinetics to
recombinant virus in which gene 4 expression was not disrupted. Both types of viruses exhibited similar virulence when
analyzed in a murine model of encephalitis. These results establish a targeted recombination system for inserting mutations
into MHV–JHM. Furthermore, the protein encoded by ORF 4 is not essential for growth in tissue culture cells or in the CNS
of the infected host. © 2001 Academic Press
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lINTRODUCTION
The genome of mouse hepatitis virus (MHV), a coro-
navirus, is a 31-kb positive-strand RNA molecule. The
large size of the genome has until recently made its
genetic manipulation difficult. The development of target
recombination has facilitated site-directed mutagenesis
of the structural genes of MHV, which reside in the
39-most 9 kb of the genome (Koetzner et al., 1992; Kuo et
l., 2000; Masters, 1999; Phillips et al., 1999). More re-
cently, infectious cDNA clones have been developed for
other coronaviruses (Almazan et al., 2000; Thiel et al.,
2001; Yount et al., 2000) and it is likely that one will
become available for MHV as well. In targeted recombi-
nation, a donor RNA transcript containing the 39 end of
the genome is introduced into cells infected with a re-
cipient virus. Recombination between the donor RNA
and the recipient virus results in recombinants that can
be selected based on either the loss of temperature
sensitivity or the host cell specificity. This method has
been used most widely to create recombinant viruses of
MHV strain A59 (Fischer et al., 1997; Kuo et al., 2000;
asters, 1999; Phillips et al., 1999) and transmissible
astroenteritis virus (Sanchez et al., 1999).
The first gene of MHV occupies the 59-most two-thirds
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230f the genome and encodes the RNA replicase. All down-
tream ORFs are expressed by synthesis of a set of
ested subgenomic mRNAs, each containing a common
eader sequence and 39 terminus (Lai and Cavanagh,
997). Homology between the leader sequence and a
egion upstream of each ORF [the intergenic sequence
IGS)] is involved in mRNA formation, although the mech-
nism of this process is not well established (Mizutani et
l., 2000; van Marle et al., 1999). In general, only the
9-most ORF in each mRNA is translated. At least three of
he downstream ORFs of the MHV genome, ORF 2a, ORF
, and ORF 5a, are nonessential for growth in tissue
ulture, as demonstrated by analysis of natural variants
f various strains (Schwarz et al., 1990; Yokomori and Lai,
991).
A previous study showed that transcription of gene 4
as not required for growth in the mouse (Yokomori and
ai, 1991). This conclusion was based on an analysis of
HV strain S, a strain of MHV that causes hepatitis in
ice. MHV-S was shown not to express mRNA 4, most
ikely due to a point mutation in the IGS (AAUUUAAAC,
instead of the canonical AAUCUAAAC). In addition, ORF
4 of another strain, MHV-A59, contains a single nucleo-
tide deletion that results in premature termination after
amino acid 19. A second potential ORF is present down-
stream of this frameshift, but only the upstream 19 amino
acid peptide was detected after translation in a cell-free
system (Weiss et al., 1993).MHV–JHM is a neurotropic strain that causes both
acute viral encephalitis and chronic demyelination. In
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231MOUSE HEPATITIS VIRUS STRAIN JHM DOES NOT AFFECT CNScontrast to MHV-A59 and MHV-S, ORF 4 of MHV–JHM
encodes a protein of 139 amino acids, rich in threonines
and containing a highly hydrophobic amino-terminal re-
gion (Skinner and Siddell, 1985). This protein has been
detected in infected cells, although its function is un-
known (Ebner et al., 1988). The presence of a full-length
ORF 4 protein in MHV–JHM-infected cells raises the
possibility that this protein contributes to the neurotro-
pism exhibited by the JHM strain. Since an infectious
cDNA clone for MHV–JHM is not yet available, we de-
veloped a system to introduce mutations into this virus
by targeted recombination. This method was used to
mutate gene 4, and the resulting virus was analyzed for
growth in tissue culture cells and in the murine CNS.
RESULTS
Construction of a general recipient virus for site-
directed mutagenesis of MHV–JHM
The original development of targeted RNA recombina-
tion as a means to manipulate the coronavirus genome
was enabled by the discovery of a thermolabile N gene
mutant of MHV-A59, Alb4, which could be counter-
selected to obtain recombinants (Koetzner et al., 1992;
Masters, 1999). Since similar counterselectable markers
have not been identified in other coronaviruses, the ap-
plication of targeted recombination has largely been lim-
ited to MHV-A59. More recently, however, it was shown
that the stringent species specificity of MHV-A59 could
be switched from murine to feline cells by replacement of
the ectodomain of the MHV S protein with that of the
feline coronavirus FIPV (Kuo et al., 2000). This created an
interspecies chimera, designated fMHV, from which, in
turn, new MHV mutants could be generated by restora-
tion of the MHV S protein ectodomain and selection for
the reacquisition of the ability to grow in murine cells. In
principal, a similar procedure should allow the construc-
tion of mutants of any strain of MHV.
To apply this method to the JHM strain of MHV, we
used the same donor RNA, from vector pFM1, that had
been used to create fMHV (strain A59) (Kuo et al., 2000).
HV–JHM-infected mouse cells were transfected with
FM1 RNA and plated onto feline cell monolayers. Re-
ulting recombinant viruses were plaque-purified in fe-
ine cells, and six recombinants, representing three in-
ependent isolates, were analyzed. It should be noted
hat the resulting viruses, designated fMHV-JHM, were
ctually composed of segments of three coronavirus
enomes (Fig. 1A). The largest part of the genome, the
2-kb gene 1, as well as gene 2a and the 59 portion of the
E gene, came from MHV–JHM. The segment of the S
ene encoding the S protein ectodomain came from
IPV, and all remaining parts of the 39 third of the ge-
ome were derived from MHV-A59. The possibility thatecombinants contained additional crossovers down-
tream of the S gene between donor RNA and the MHV–HM recipient was not tested, since this portion of the
enome was to be exchanged back to MHV–JHM in
ubsequent mutant construction. One recombinant,
MHV-JHM B3b, was chosen for further work since its HE
ene contained the largest 59 extent of the MHV–JHM HE
ene, crossing over into MHV-A59 sequence in a region
f identity between the two strains between 159 and 149
t upstream of the HE gene stop codon.
onstruction of MHV–JHM gene 4 KO and control
ecombinants
To generate mutants of MHV-JHM, a vector for the
ynthesis of donor RNA for targeted recombination was
onstructed. This vector was created by the stepwise
eplacement in plasmid pMH54 of MHV-A59 genes 3–7
the S gene through the N gene) with their MHV–JHM
ounterparts (Fig. 2). In the resulting construct, pJHM, the
ragment of the HE gene of MHV-A59 was retained be-
ause it is minimally divergent from that of MHV–JHM
nd because it is not expressed in either MHV-A59 or in
ur laboratory strain of MHV–JHM. Likewise, the 39-UTR
of MHV-A59 was retained, since it differs from that of
MHV–JHM at only a single nucleotide. To inactivate ex-
pression of gene 4, three sets of mutations were intro-
duced into pJHM to produce pJHM-gene4KO (Fig. 2).
First, the IGS upstream of gene 4 was made identical to
the one present in MHV-S, the natural variant that does
not transcribe gene 4 (Yokomori and Lai, 1991). Second,
a premature stop codon was engineered in place of
amino acid 18. Finally, a downstream AUG at codon 23
was mutated to CGA. A termination codon is present in
MHV-A59 at approximately the same location in ORF 4
and may result in usage of the downstream AUG. Al-
though usage of this AUG has never been demonstrated,
this mutation removed it from our construct. This last
change also introduced a SalI restriction site, useful for
screening purposes.
Targeted recombination was then used to generate
gene 4 KO recombinants (RJHM.gene4KO) and wild-type
MHV–JHM controls (RJHM.wt) (Fig. 1B). Donor RNA was
transcribed from pJHM or pJHM-gene4KO and was trans-
fected into FCWF cells that had been infected with
fMHV–JHM B3b. Virus was subsequently harvested from
these infected–transfected cells, and recombinants ex-
pressing the MHV–JHM S protein were selected on mu-
rine cells and then plaque-purified. Sequencing of RT-
PCR products from RNA harvested from cells infected
with the gene 4 KO recombinants confirmed the pres-
ence of the three sets of mutations introduced into the
gene 4 region.
In each case, two MHV–JHM recombinants, harvested
from separate flasks of murine cells, were analyzed to
reduce the possibility that any observed viral phenotype
was due to a secondary random mutation.
eprese
ed rec
232 ONTIVEROS ET AL.Analysis of JHM recombinants
We next determined whether the mutations introduced
into the gene 4 KO mutant had the expected effects on
transcription and translation. The levels of viral RNA in
infected cells were assessed by Northern blot analysis
(Fig. 3). As expected, two bands corresponding to mRNA
4 and 5 were clearly visualized from cells infected with
MHV-A59 or wild-type MHV–JHM (lanes 2 and 3). Sur-
prisingly, only a faint band corresponding to mRNA 5 was
detected in cells infected with recombinant wild-type or
mutant MHV–JHM (lanes 4 and 5). This result was unex-
pected because the E protein, encoded by gene 5b, is
essential for virus assembly, although only low levels
may be required (Bos et al., 1996; Raamsman et al., 2000;
Vennema et al., 1996; Yu et al., 1994). The mechanism by
which transcription of mRNA 5 is decreased in the MHV–
JHM recombinants is unknown.
As also seen in Fig. 3, the amount of mRNA 4 in cells
infected with recombinant wild-type virus was greater
FIG. 1. Strategy for site-directed mutagenesis of MHV-JHM. (A) Co
recombination. MHV–JHM-infected mouse cells were transfected with d
selected as a recombinant capable of growth in feline cells. (B) Con
transfected with donor RNA transcribed from pJHM or from pJHM-ge
growth in mouse cells. The mutated region in pJHM-gene4KO RNA is r
segments are indicated by open rectangles for MHV–JHM, crosshatchthan that observed in cells infected with MHV–JHM
(lanes 3 and 4). This upregulation of transcription is aconsequence of the three nucleotide changes made by
the introduction of an Sse8387I restriction site upstream
of the gene 4 IGS (Fig. 2), although the mechanism for
this enhancement remains to be determined (X. Shen,
and P. S. Masters, unpublished results). Only a low level
of subgenomic mRNA 4 was detected by Northern blot
analysis in cells infected with RJHM.gene4KO.1 (Fig. 3,
lane 5). Thus, the point mutation in the IGS severely
reduced transcription of mRNA 4 but did not entirely
eliminate it. This point mutation is sufficient to com-
pletely abolish mRNA 4 transcription as measured by
Northern blot analysis in MHV-S (18), but in the context of
the upregulating Sse88387I mutations, a residual level of
transcription was unmasked.
To determine the effect of the gene 4 KO reading frame
mutations on translation, DNA containing ORF 4 from
control and mutated plasmids was subcloned and tran-
scribed as described under Materials and Methods. The
RNA was translated in a wheat germ extract and the
ion of the interspecies chimeric mutant fMHV-JHM B3b by targeted
NA transcribed from pFM1 (Kuo et al., 2000), and fMHV–JHM B3b was
n of MHV–JHM recombinants. fMHV–JHM-infected feline cells were
and MHV–JHM mutants were selected as recombinants capable of
nted by a star. In both A and B, the sources of genomic or donor RNA
tangles for MHV-A59, and shaded rectangles for FIPV.nstruct
onor R
structio
ne4KO,products analyzed by SDS–PAGE. As shown in Fig. 4, an
approximately 15-kDa band was translated from control
R
o
the po
2000;
233MOUSE HEPATITIS VIRUS STRAIN JHM DOES NOT AFFECT CNSmRNA, which accords well with the predicted molecular
weight of 15.2 kDa for this protein. This band was absent
when ORF 4 KO RNA was translated. A second band,
migrating at approximately 28 kDa, was also apparent
when wild-type RNA, but not ORF 4 KO RNA, was trans-
lated. This band was not further identified. Of note, we
were unable to detect a 2-kDa protein expected to result
from translation of the gene 4 KO product (Weiss et al.,
1993), even after analysis on 20% polyacrylamide gels.
Growth in tissue culture cells
Previous results showed that gene 4 transcription was
not required for growth in tissue culture cells (Yokomori
and Lai, 1991). As shown in Fig. 5, all the recombinant
viruses exhibited a delayed eclipse period when com-
pared to nonrecombinant wild-type virus. Between the
gene 4 KO and wild-type recombinant viruses, however,
there were no differences in growth kinetics. Approxi-
FIG. 2. Construction of plasmids for targeted recombination. Plasmid
2000), served as the starting point for construction of pJHM, in whic
corresponding sequences from MHV–JHM, as detailed under Mater
rectangles for MHV–JHM and crosshatched rectangles for MHV-A59. I
created in pJHM-gene4KO to inactivate expression of gene 4 are indica
mutation in MHV-S (Yokomori and Lai, 1991); (ii) a premature stop codo
codon 23. Also shown underlined are the start codon for ORF 4 and
introduced to facilitate the exchange of S gene sequences (Kuo et al.,mately the same titers of virus were obtained by 24 h p.i.
with the recombinant and nonrecombinant viruses. Allthe viruses also caused similar cytopathic effects and
syncytia formation.
Growth in the infected murine CNS
Although these results showed that gene 4 expression
was not required for growth in tissue culture cells, it may
still be important for growth in the infected animal host.
To determine the virulence of the gene 4 KO virus,
C57Bl/6 mice were infected by intracranial inoculation
with this virus and the control viruses in LD50 assays.
JHM.wt.1 had an LD50 of 3 PFU, similar to what was
bserved for nonrecombinant wild-type MHV–JHM (LD50
of 1 PFU) (Table 1). The average LD50 of the MHV–JHM
gene 4 KO recombinants was 2.4 PFU, which was not
significantly different from the wild-type viruses. All vi-
ruses replicated to similar levels when viral titers were
measured at day 5 postinfection. Virus was harvested
from infected mice and subjected to Northern blot anal-
4-S4 (Phillips et al., 1999), which was derived from pMH54 (Kuo et al.,
HV-A59 S gene and all genes downstream were replaced with the
d Methods. The sources of cDNA segments are indicated by open
gment of sequence shown at the bottom, the three sets of mutations
bold: (i) a point mutation at the fourth position of IGS4, identical to the
duced at codon 18; and (iii) abolition of a second potential start site at
int mutations originally placed in pMH54 to create an Sse8387I site,
Phillips et al., 1999).pMH5
h the M
ials an
n the se
ted in
n introysis after one passage through tissue culture cells. As in
cells infected with input virus, gene 4 RNA was detected
Rm
234 ONTIVEROS ET AL.only at low levels in cells infected with the CNS-derived
gene 4 KO virus (data not shown). The continued pres-
ence of the three mutations introduced into MHV–JHM
gene 4 KO mutant was confirmed by sequence analysis.
No differences in virulence were obtained when mice
FIG. 3. Northern blot analysis of recombinant viral RNA. RNA was
isolated from cells infected with recombinant or nonrecombinant virus
as indicated and processed for Northern blot analysis as described
under Materials and Methods. MHV-specific RNA was detected using
a 32P-labeled oligodeoxynucleotide probe complementary to the N
gene. MHV RNAs 1 (genomic RNA) and 2–7 (subgenomic mRNAs) are
indicated on the left. Lane 1, mock-infected. Lane 2, MHV-A59. Lane 3,
nonrecombinant wild-type MHV-JHM. Lane 4, RJHM.wt.1. Lane 5,
RJHM.gene4KO.1.
FIG. 4. In vitro translation of gene 4 RNA. RNA was transcribed from
plasmids encoding wild-type gene 4 or gene 4 KO sequence, as
described under Materials and Methods. RNA was translated in a
wheat germ extract labeled with [35S]methionine and the protein prod-
ucts were analyzed in a 12% SDS–polyacrylamide gel under reducing
conditions. Lane 1, wild-type MHV–JHM gene 4. Lane 2, MHV–JHM
gene 4 KO. Mobilities of molecular weight markers are indicated on the
left.were inoculated intranasally with the gene 4 KO and
wild-type viruses (data not shown).
To determine whether the pattern of spread or cell
tropism was altered by the absence of the gene 4 prod-
uct, brains from mice intracranially infected with gene 4
KO and wild-type virus were analyzed by immunohisto-
chemistry with a monoclonal antibody against the nu-
cleocapsid protein. No gross differences in the localiza-
tion of virus antigen or extent of infection were detected
in the brains of mice infected with the different viruses
(Fig. 6). Also, the gene 4 KO and wild-type viruses all
infected both the white and the gray matter, suggesting
that there was not a significant change in cell tropism
mediated by gene 4. Infection with all three viruses
resulted in an intense inflammatory response, with wide-
spread perivascular cuffing and mononuclear cell infil-
tration into the parenchyma.
FIG. 5. Kinetics of virus production in 17Cl-1 cells. Cells were in-
fected with nonrecombinant and recombinant viruses at a multiplicity of
infection of 1 PFU/cell. Cells and supernatant were harvested at the
indicated times and freeze-thawed. Titers were measured by plaque
assay on HeLa-MHVR cells. M, RJHM.wt.1; f, RJHM.wt.2; E,
RJHM.gene4KO.1; F, RJHM.gene4KO.2; l, MHV–JHM.
TABLE 1
Virulence in the CNS After Intracranial Inoculation
Virulence
(LD50)
a
Average brain
viral titers
log10 (pfu/g) 6 S.E.
b
Nonrecombinant wild-type 1 ND
JHM.wt.1 3 5.1 6 0.31
RJHM.gene4KO.1 1 5.75 6 0.32
RJHM.gene4KO.2 3.8 6.23 6 0.13
a Four C57Bl/6 mice per dilution were inoculated with virus and
onitored.
b LD50 were performed as described under Materials and Methods.
Titers were determined at days 6–7 p.i.
ND, not done.
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235MOUSE HEPATITIS VIRUS STRAIN JHM DOES NOT AFFECT CNSDISCUSSION
Previous studies have established the utility of tar-
eted recombination for studying the molecular biology
nd pathogenesis of coronaviruses, principally the A59
train of MHV. In initial studies, recombinant MHV-A59
as generated by infecting cells with a parental strain
ontaining a large deletion in the nucleocapsid (N) pro-
ein and transfecting donor RNA containing the full-
ength N gene as well as a mutation of interest (Koetzner
t al., 1992; Masters, 1999). The deletion rendered the
irus thermolabile and it was relatively straightforward to
solate recombinant virus. This method was limited, how-
ver, to strains of virus for which a counterselectable
utation was available. More recently, a strategy was
eveloped based on the stringent host cell specificity
xhibited by coronaviruses. This method, originally de-
eloped using MHV-A59 containing the S glycoprotein of
IPV (Kuo et al., 2000), allowed the selection of recom-
binants based on host cell species restriction.
In the present work, we show that this methodology is
generally useful for the study of coronavirus pathogene-
FIG. 6. Wild-type and gene 4 KO recombinants cause similar patho-
logic changes in the CNS of infected B6 mice. B6 mice were infected
intracranially with 100 PFU of recombinant virus. Mice were sacrificed
at day 5, when moribund, and brains and spinal cords were prepared
as described under Materials and Methods. Sections were analyzed for
the presence of virus antigen by immunohistochemistry. (A, C)
RJHM.wt.1. (B, D) RJHM.gene4KO.2. (A, B) Cerebral cortex. (C, D) Hip-
pocampus. Magnification bar, 125 mm.sis. Several strains of MHV, including MHV–JHM, MHV-2,
and MHV-3, cause different diseases and pathologic
p
1changes in mice. In a number of cases, S protein has
been shown to be a major determinant in these patho-
genic differences. In one study, introduction of the S
protein of MHV–JHM into MHV-A59 created a virus with
neurovirulence nearly identical to that of MHV–JHM (Phil-
lips et al., 1999). In other studies, the S protein was
shown to be critical for demyelination caused by MHV-
A59 and for the development of hepatitis (Das Sarma et
al., 2000; Navas et al., 2001). While the S protein is clearly
very important in disease pathogenesis, other genes are
likely to also play contributory roles. Using the method-
ology that we describe in this paper, it should be possi-
ble to develop any of these viruses as the recipient virus
for targeted recombination. It will then be feasible to
investigate the role of individual 39 genes of MHV in the
ontext of different MHV strains.
Using this approach, our data confirm previous reports
howing that the product of ORF 4 is not required for
rowth in tissue culture cells (Weiss et al., 1993;
okomori and Lai, 1991). Neither the growth kinetics,
ytopathogenicity, nor maximal titers appeared to be
ffected by the deletion of the ORF 4 product. In agree-
ent with a previous report, mutation of the intergenic
equence resulted in great diminution in the level of
ubgenomic mRNA 4 (Yokomori and Lai, 1991). This re-
ult is particularly striking in our recombinant viruses,
ince the level of subgenomic mRNA 4 is greatly in-
reased in wild-type recombinant virus by the introduc-
ion of an Sse8387I restriction site into the plasmid used
o transcribe donor RNA. As a consequence of the ele-
ated transcription level of mRNA 4, low levels of this
ranscript from the MHV–JHM gene 4 KO recombinant
ere detectable by Northern blot analysis (Fig. 3). Intro-
uction of two additional mutations eliminated synthesis
f full-length ORF 4 protein product despite leaky tran-
cription (Fig. 4).
We failed to show a role for the ORF 4 protein in the
athogenesis of acute encephalitis. Previous analyses of
HV-S, the natural variant of MHV lacking gene 4 tran-
cription, suggested that the ORF 4 protein was not
equired for the development of hepatitis. Thus, the ORF
product is not required for manifestation of two of the
iseases caused by the MHV family. The ORF 4 product
ay still be involved in the pathogenesis of enteritis, a
isease not caused by MHV–JHM, but a site infected by
ther strains of MHV (Compton et al., 1993). Also, even
hough we showed that the gene 4 KO virus is able to
nfect the white matter of the CNS, it is also possible that
t has a role in viral persistence. Although the protein
roduct of ORF 4 is not required, it is possible that the
ene 4 sequence is required for proper folding of the
NA genome. The gene 4 RNA sequence is not abso-
utely necessary, however, since virus in which most of
ene 4 was replaced by the gene for green fluorescent
rotein was viable in tissue culture cells (Fischer et al.,
997).
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236 ONTIVEROS ET AL.Recombinant MHV–JHM and the gene 4 KO variants
all exhibited a longer eclipse period than did nonrecom-
binant wild-type virus when grown in tissue culture cells.
A notable difference between the recombinant and non-
recombinant viruses was enhanced transcription of gene
5 in the latter. Gene 5 contains two open reading frames
and the downstream one, gene 5b, encodes the E pro-
tein, essential in viral assembly and egress from the cell
(Maeda et al., 1999; Vennema et al., 1996; Yu et al., 1994).
Diminished expression of the E protein by the recombi-
nant viruses may result in a delay in virus assembly with
a concomitant decrease in growth kinetics. Strikingly,
this delay in tissue culture kinetics did not affect viru-
lence in mice, since recombinant and nonrecombinant
viruses were equally lethal after intracerebral inoculation
(Table 1).
Our study shows that targeted recombination will be
useful for studies of MHV–JHM pathogenesis. Targeted
recombination is particularly useful for studying the
structural proteins encoded at the 39 end of the corona-
virus genome. This method will complement approaches
based on infectious clones now being developed
(Almazan et al., 2000; Thiel et al., 2001; Yount et al., 2000).
MATERIALS AND METHODS
irus and cells
MHV–JHM was grown and titered as previously de-
cribed (Perlman et al., 1987). An interspecies chimeric
ecombinant virus (designated fMHV–JHM clone B3b)
as selected exactly as previously described for fMHV
MHV-A59) (Kuo et al., 2000), except that MHV–JHM was
sed as the recipient in recombination (Fig. 1A). fMHV–
HM B3b contains genes 1 and 2a of MHV–JHM, the 59
nd of the HE gene of MHV-JHM, followed by the 39 end
of the HE gene of MHV-A59, the ectodomain of the spike
glycoprotein (S) gene of feline infectious peritonitis virus
(FIPV), followed by the transmembrane and endodo-
mains of the S gene of MHV-A59, and gene 4 through the
39-UTR of MHV-A59 (Fig. 1A). fMHV–JHM B3b virus was
plaque-purified and propagated in feline FCWF cells. All
recombinant viruses encoding an MHV S protein were
propagated in either mouse 17Cl-1 cells or DBT cells.
Recombinant viruses were plaque-purified on 17Cl-1
cells and titered on HeLa cells expressing the MHV
receptor (HeLa-MHVR, kindly provided by Dr. T. Gal-
lagher, Loyola School of Medicine).
Plasmids and PCR mutagenesis
A vector for synthesis of MHV–JHM donor RNA for
targeted recombination was constructed from plasmid
pMH54-S4 (Phillips et al., 1999) (kindly provided by Su-
san Weiss, University of Pennsylvania). pMH54-S4 was
derived from pMH54, which contains the 59-most 0.46 kb
of the MHV-A59 genome fused to the 39-most 8.6 kb ofthe MHV-A59 genome, beginning at codon 28 of the HE
gene (6) (Fig. 2). In pMH54-S4, the MHV–JHM S gene
replaces that of MHV-A59. The sequences for MHV–JHM
genes 4, 5a, E, M, and N were PCR amplified from
plasmids (a gift from Dr. S. Siddell, University of Wurz-
berg) or from RNA harvested from 17Cl-1 cells infected
with MHV–JHM and inserted into pMH54-S4 to create
pJHM (Fig. 2). To create a recombinant virus in which
expression of gene 4 was disrupted, three sets of muta-
tions were introduced into pJHM using PCR mutagenesis
to create pJHM-gene4KO (Fig. 2). An upstream PCR prod-
uct was synthesized using a 59 primer containing a
unique Sse8387I restriction site (bold) and a mutation in
the intragenic region (underlined) (59-CAGCC CCTG-
AGGAAAGACAGAAAATTTAAAC-39). The downstream
(reverse) primer was constructed to introduce a termina-
tion codon at amino acid 18 (bold) and to inactivate a
downstream methionine at residue 23 (underlined) (59-
TGCCTAGTCGACATGC TACTAG TTATGGAC-39). A SalI
site was introduced as part of the latter process (Fig. 2).
A second PCR product was synthesized using an up-
stream primer complementary to the downstream primer
of the first PCR product and a 39 primer encompassing a
unique EagI restriction site (underlined) within the trans-
membrane (M) gene (59-CGGCCTCGTCGGCCG TCCAT-
TGGT-39). A final PCR product was synthesized using the
two outer primers and introduced into pJHM after restric-
tion with Sse8387I and EagI.
To produce mRNA for cell-free translation, MHV–JHM
ORF 4 and its ORF 4 KO counterpart were cloned into
pIBI (Kodak-IBI). Wild-type or mutant ORF 4 sequence
was PCR amplified from pJHM or pJHM-gene4KO, re-
spectively, and ligated into pIBI downstream of the T7
bacteriophage RNA polymerase promoter. The PCR
product included ORF 4 and an additional 24 upstream
bases but did not contain the upstream IGS. The fidelity
of the sequences of all clones was verified using an
automated sequencer (ABI 373A Stretch Sequencer; Ap-
plied Biosystems, Foster City, CA).
Targeted recombination
Targeted RNA recombination was carried out essen-
tially as described previously (Kuo et al., 2000). To con-
struct the fMHV–JHM mutant, mouse L2 cells infected
with MHV–JHM were transfected with donor RNA tran-
scribed from pFM1, and recombinants were selected by
growth on feline FCWF cells. To construct MHV–JHM
derivatives, feline cells infected with fMHV–JHM B3b
were transfected with donor RNAs transcribed from
pJHM or pJHM-gene4KO, and recombinants were se-
lected by growth on 17Cl-1 cells. Resulting recombinants
were plaque-purified twice on permissive cells. To verify
the compositions of relevant segments of recombinant
viral genomes, cDNA was prepared from virus-infected
cells, and PCR-amplified regions were sequenced. For
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rived from independent recombination events were char-
acterized.
In vitro transcription and translation
Plasmids used for in vitro transcription were linearized
ith PacI (pJHM and pJHM gene 4 KO) or EcoRI (pIBI)
and purified by proteinase K/SDS treatment followed by
phenol/chloroform extraction and ethanol precipitation.
Synthetic capped RNAs were transcribed using a mMES-
SAGE mMACHINE T7 Kit (Ambion, Inc., Austin, TX) as
recommended by the manufacturer except that GTP was
added to a final concentration of 4.5 mM. In vitro trans-
lation using a wheat germ extract kit (Promega, Madison,
WI) was performed as recommended by the manufac-
turer except that potassium acetate was added to a final
concentration of 113 mM. Briefly, 0.25 mg ORF4 wild-type
RNA or ORF4 KO mRNA was added to wheat germ
xtract supplemented with essential amino acids lacking
ethionine and with [35S]methionine. Reactions were
incubated at 27°C for 1 h. Samples were analyzed by
electrophoresis through 12% polyacrylamide-reducing
gels containing SDS.
Growth kinetics in tissue culture
Confluent 17Cl-1 monolayers were infected with re-
combinant MHV at a multiplicity of 1 PFU per cell and
allowed to adsorb for 30 min with rocking every 5 min.
Following absorption, cells were washed twice with PBS
and covered with media. Samples were harvested at the
times indicated, and viral titers were determined on
HeLa–MHVR cells.
Virulence assay in mice and virus titers in CNS
Virulence was assayed by determining the dose of
virus that killed 50% of mice (LD50). Briefly, 5- to 6-week-
ld pathogen-free C57Bl/6 male mice (National Cancer
nstitute, Frederick, MD) were inoculated intracranially
ith 30 ml of serial threefold dilutions of virus ranging
from 0.3 to 100 PFU. Mice were monitored daily for signs
of morbidity. The LD50 was calculated using the Reed–
Muench method (Reed and Muench, 1938; Smith and
Barthold, 1997). To measure virus titers in the CNS,
brains were harvested from infected mice at day 5
postinfection (p.i.). Brains were homogenized and freeze-
thawed before titering on HeLa-MHVR cells.
Isolation of RNA from infected tissue culture cells
and CNS tissue
Mice were infected with virus intracranially. When
mice were moribund, mice were sacrificed and one half
of each brain was harvested. After dispersion with a
glass homogenizer and clarification, 1 ml (representing
10% of the brain) was plated onto confluent 17 Cl-1 cells.RNA was harvested from infected cells using TriReagent
(Molecular Research Center, Inc., Cincinnati, OH) as de-
scribed previously (Pewe et al., 1996). To confirm that no
hanges in ORF 4 occurred during passage in the CNS,
DNA was prepared and PCR-amplified ORF 4 was se-
uenced. For Northern blot analysis, 20 mg of total cel-
lular RNA was separated by gel electrophoresis as pre-
viously described (Perlman et al., 1990). Asymmetric PCR
was used to synthesize a 32P-labeled 70-base DNA probe
complementary to the gene encoding the nucleocapsid
(N) protein. This probe detected all viral transcripts.
Histology and immunohistochemistry
Brains were harvested from infected mice on days 5–7
p.i. after sacrifice and perfusion with PBS. Brains were
embedded in Histochoice (Amresco, Solon, OH) or zinc
formalin (Labsco, Louisville, KY), sectioned, and stained
with hematoxylin and eosin. Viral antigen was detected
using an antinucleocapsid (N) antibody as described
previously (Sun et al., 1995).
ACKNOWLEDGMENTS
This work was supported by grants from the NIH (NS 36592 and NS
40438 to S.P.; AI 39544 to P.S.M.) and the National Multiple Sclerosis
Society (S.P.). E.O. was supported by an NIH predoctoral National
Research Service Award (F31 AI10348). We thank Joanna Phillips and
Susan Weiss for plasmids and helpful discussion.
REFERENCES
Almazan, F., Gonzalez, J. M., Penzes, Z., Izeta, A., Calvo, E., Plana-Duran,
J., and Enjuanes, L. (2000). Engineering the largest RNA virus ge-
nome as an infectious bacterial artificial chromosome. Proc. Natl.
Acad. Sci. USA 97, 5516–5521.
os, E. C., Luytjes, W., van der Meulen, H. V., Koerten, H. K., and Spaan,
W. J. M. (1996). The production of recombinant infectious DI-particles
of a murine coronavirus in the absence of helper virus. Virology 218,
52–60.
Compton, S. R., Barthold, S. W., and Smith, A. L. (1993). The cell and
molecular pathogenesis of coronaviruses. Lab. Anim. Sci. 43, 15–28.
Das Sarma, J., Fu, L., Tsai, J. C., Weiss, S. R., and Lavi, E. (2000).
Demyelination determinants map to the spike glycoprotein gene of
coronavirus mouse hepatitis virus. J. Virol. 74, 9206–9213.
Ebner, D., Raabe, T., and Siddell, S. G. (1988). Identification of the
coronavirus MHV-JHM mRNA 4 product. J. Gen. Virol. 69, 1041–1050.
Fischer, F., Stegen, C., Koetzner, C. A., and Masters, P. S. (1997).
Analysis of a recombinant mouse hepatitis virus expressing a foreign
gene reveals a novel aspect of coronavirus transcription. J. Virol. 71,
5148–5160.
Koetzner, C. A., Parker, M. M., Ricard, C. S., Sturman, L. S., and Masters,
P. S. (1992). Repair and mutagenesis of the genome of a deletion
mutant of the coronavirus mouse hepatitis virus by targeted RNA
recombination. J. Virol. 66, 1841–1848.
Kuo, L., Godeke, G. J., Raamsman, M. J., Masters, P. S., and Rottier, P. J.
(2000). Retargeting of coronavirus by substitution of the spike glyco-
protein ectodomain: Crossing the host cell species barrier. J. Virol.
74, 1393–1406.
Lai, M. M. C., and Cavanagh, D. (1997). The molecular biology of
coronaviruses. Adv. Virus Res. 48, 1–100.
Maeda, J., Maeda, A., and Makino, S. (1999). Release of coronavirus E
M238 ONTIVEROS ET AL.protein in membrane vesicles from virus-infected cells and E protein-
expressing cells. Virology 263, 265–272.
Masters, P. S. (1999). Reverse genetics of the largest RNA viruses. Adv.
Virus Res. 53, 245–264.
izutani, T., Repass, J. F., and Makino, S. (2000). Nascent synthesis of
leader sequence-containing subgenomic mRNAs in coronavirus ge-
nome-length replicative intermediate RNA. Virology 275, 238–243.
Navas, S., Seo, S. H., Chua, M. M., Sarma, J. D., Lavi, E., Hingley, S. T.,
and Weiss, S. R. (2001). Murine coronavirus spike protein determines
the ability of the virus to replicate in the liver and cause hepatitis.
J. Virol. 75, 2452–2457.
Perlman, S., Jacobsen, G., Olson, A. L., and Afifi, A. (1990). Identification
of the spinal cord as a major site of persistence during chronic
infection with a murine coronavirus. Virology 175, 418–426.
Perlman, S., Schelper, R., Bolger, E., and Ries, D. (1987). Late onset,
symptomatic, demyelinating encephalomyelitis in mice infected with
MHV-JHM in the presence of maternal antibody. Microb. Pathog. 2,
185–194.
Pewe, L., Wu, G., Barnett, E. M., Castro, R., and Perlman, S. (1996).
Cytotoxic T cell-resistant variants are selected in a virus-induced
demyelinating disease. Immunity 5, 253–262.
Phillips, J. J., Chua, M. M., Lavi, E., and Weiss, S. R. (1999). Pathogenesis
of chimeric MHV4/MHV-A59 recombinant viruses: The murine coro-
navirus spike protein is a major determinant of neurovirulence.
J. Virol. 73, 7752–7760.
Raamsman, M. J., Locker, J. K., de Hooge, A., de Vries, A. A., Griffiths, G.,
Vennema, H., and Rottier, P. J. (2000). Characterization of the coro-
navirus mouse hepatitis virus strain A59 small membrane protein E.
J. Virol. 74, 2333–2342.
Reed, L. J., and Muench., H. (1938). A simple method of estimating fifty
percent points. Am. J. Hyg. 27, 493–497.
Sanchez, C. M., Izeta, A., Sanchez-Morgado, J. M., Alonso, S., Sola, I.,
Balasch, M., Plana-Duran, J., and Enjuanes, L. (1999). Targeted re-
combination demonstrates that the spike gene of transmissible gas-
troenteritis coronavirus is a determinant of its enteric tropism and
virulence. J. Virol. 73, 7607–7618.Schwarz, B., Routledge, E., and Siddell, S. G. (1990). Murine coronavirus
nonstructural protein ns2 is not essential for virus replication in
transformed cells. J. Virol. 64, 4784–4791.
Skinner, M. A., and Siddell, S. G. (1985). Coding sequence of corona-
virus MHV-JHM mRNA 4. J. Gen. Virol. 66, 593–596.
Smith, A. L., and Barthold, S. W. (1997). Methods in viral pathogenesis.
In “Viral Pathogenesis” (N. Nathanson, Ed.), pp. 483–506. Lippincott-
Raven, Philadelphia, PA.
Sun, N., Grzybicki, D., Castro, R., Murphy, S., and Perlman, S. (1995).
Activation of astrocytes in the spinal cord of mice chronically infected
with a neurotropic coronavirus. Virology 213, 482–493.
Thiel, V., Herold, J., Schelle, B., and Siddell, S. G. (2001). Infectious RNA
transcribed in vitro from a cDNA copy of the human coronavirus
genome cloned in vaccinia virus. J. Gen. Virol. 82, 1273–1281.
van Marle, G., Dobbe, J. C., Gultyaev, A. P., Luytjes, W., Spaan, W. J., and
Snijder, E. J. (1999). Arterivirus discontinuous mRNA transcription is
guided by base pairing between sense and antisense transcription-
regulating sequences. Proc. Natl. Acad. Sci. USA 96, 12056–12061.
Vennema, H., Godeke, G.-J., Rossen, J. W. A., Voorhout, W. F., Horzinek,
M. C., Opstelten, D.-J. E., and Rottier, P. J. M. (1996). Nucleocapsid-
independent assembly of coronavirus-like particles by co-expression
of viral envelope protein genes. EMBO J. 15, 2020–2028.
Weiss, S. R., Zoltick, P. W., and Leibowitz, J. L. (1993). The ns 4 gene
of mouse hepatitis virus (MHV), strain A 59 contains two ORFs and
thus differs from ns 4 of the JHM and S strains. Arch. Virol. 129,
301–309.
Yokomori, K., and Lai, M. M. C. (1991). Mouse hepatitis virus S RNA
sequence reveals that nonstructural protein ns4 and ns5a are not
essential for murine coronavirus replication. J. Virol. 65, 5605–5608.
Yount, B., Curtis, K. M., and Baric, R. S. (2000). Strategy for systematic
assembly of large RNA and DNA genomes: Transmissible gastroen-
teritis virus model. J. Virol. 74, 10600–10611.
Yu, X., Bi, W., Weiss, S. R., and Leibowitz, J. L. (1994). Mouse hepatitis
virus gene 5b protein is a new virion envelope protein. Virology 202,
1018–1023.
